Overview

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of Biktarvy in Treatment-Naïve Late Presenters with HIV-1 Infection
Phase:
Phase 4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Gilead Sciences
Treatments:
Efavirenz
Lamivudine
Tenofovir